Deep Dive

Deep Dive: When the Risk Baseline and the QMS Both Break Down

Let's Talk Risk! Podcast

Discusses The baseline is completely broken and the iteration process is blind.FDA’s August 21, 2026 warning l…

Sep 25, 2026

Deep Dive: When FDA Qualifies the Ruler

Let's Talk Risk! Podcast

Discusses A qualified tool does not eliminate regulatory scrutiny. It eliminates the need to keep proving that…

Sep 18, 2026

Deep Dive: What FDA’s QMSR Warning Letters Are Revealing

Let's Talk Risk! Podcast

Discusses If you’re trying to manage risk in isolated silos, your quality management system is already obsolet…

Sep 11, 2026

Deep Dive: The PFAS Substitution Risk Paradox in Medical Devices

Let's Talk Risk! Podcast

Discusses FDA: There is no reason to restrict the continued use of fluoropolymers in medical devices.What happ…

Sep 4, 2026

Deep Dive: When Patient Preference Becomes Regulatory Evidence

Let's Talk Risk! Podcast

Discusses Patient preference is no longer a soft qualitative afterthought.What if a device carries significant…

Aug 28, 2026

Deep Dive: Designing Safety Into Autonomous Robotic Devices

Let's Talk Risk! Podcast

Discusses The vulnerability of the modern clinical lab is quite literally concentrated at the point of the nee…

Aug 21, 2026

Deep Dive: First FDA Warning Letter Under QMSR

Let's Talk Risk! Podcast

Discusses Under QMSR, FDA is not only looking for individual quality failures. It is examining how failures co…

Aug 7, 2026

Deep Dive: FDA's RWE Guidance

Let's Talk Risk! Podcast

Discusses Real-world data does not become regulatory evidence simply because it is large, current, or readily …

Jul 24, 2026